Telix Pharmaceuticals Ltd ADR Financials
This page shows Telix Pharmaceuticals Ltd ADR (TLX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Rapid revenue expansion is being absorbed by working capital and investment buildout, so scale has not yet turned into durable cash.
FY2024’s stronger liquidity was externally created: a$416.8M financing inflow lifted cash to$440.0M , but by FY2025 that cushion had been largely redeployed as investing outflow reached$285.9M and operating cash flow turned to-$17.3M . The simultaneous rise in goodwill from$66.6M to$199.0M shows the balance sheet expanded through purchased assets more than through retained cash earnings.
As sales scaled, cash conversion weakened: receivables nearly tripled from
The company still looks more equity-funded than debt-funded: long-term debt was only
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Telix Pharmaceuticals Ltd ADR's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Telix Pharmaceuticals Ltd ADR's revenue surged 55.6% year-over-year to $803.8M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Telix Pharmaceuticals Ltd ADR carries a low D/E ratio of 0.14, meaning only $0.14 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.
Telix Pharmaceuticals Ltd ADR's current ratio of 1.43 is below the typical benchmark, resulting in a score of 24/100. However, the company holds substantial cash reserves (61% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.
While Telix Pharmaceuticals Ltd ADR generated -$17.3M in operating cash flow, capex of $25.7M consumed most of it, leaving -$43.0M in free cash flow. This results in a low score of 22/100, reflecting heavy capital investment rather than weak cash generation.
Telix Pharmaceuticals Ltd ADR generates a -1.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 17/100. This is down from 9.5% the prior year.
Telix Pharmaceuticals Ltd ADR passes 1 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Telix Pharmaceuticals Ltd ADR generates $2.43 in operating cash flow (-$17.3M OCF vs -$7.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Telix Pharmaceuticals Ltd ADR generated $803.8M in revenue in fiscal year 2025. This represents an increase of 55.6% from the prior year.
Telix Pharmaceuticals Ltd ADR reported -$7.1M in net income in fiscal year 2025. This represents a decrease of 121.2% from the prior year.
Telix Pharmaceuticals Ltd ADR earned $-0.02 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 121.6% from the prior year.
Cash & Balance Sheet
Telix Pharmaceuticals Ltd ADR generated -$43.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 334.0% from the prior year.
Telix Pharmaceuticals Ltd ADR held $141.9M in cash against $56.5M in long-term debt as of fiscal year 2025.
Telix Pharmaceuticals Ltd ADR had 339M shares outstanding in fiscal year 2025. This represents an increase of 1.2% from the prior year.
Margins & Returns
Telix Pharmaceuticals Ltd ADR's net profit margin was -0.9% in fiscal year 2025, showing the share of revenue converted to profit. This is down 7.4 percentage points from the prior year.
Telix Pharmaceuticals Ltd ADR's ROE was -1.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 11.3 percentage points from the prior year.
Capital Allocation
Telix Pharmaceuticals Ltd ADR invested $25.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 181.8% from the prior year.
TLX Income Statement
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A |
TLX Balance Sheet
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|---|---|---|
| Total Assets | $1.2B+23.8% | $940.4M+239.2% | $277.3M |
| Current Assets | $330.3M-42.1% | $570.1M+259.3% | $158.7M |
| Cash & Equivalents | $141.9M-67.8% | $440.0M+422.0% | $84.3M |
| Inventory | $37.1M+57.0% | $23.6M+85.4% | $12.7M |
| Accounts Receivable | $129.2M+48.6% | $86.9M+97.4% | $44.0M |
| Goodwill | $199.0M+198.8% | $66.6M-11.3% | $75.1M |
| Total Liabilities | $748.6M+27.4% | $587.4M+236.4% | $174.6M |
| Current Liabilities | $231.6M+12.9% | $205.1M+84.1% | $111.4M |
| Long-Term Debt | $56.5M+1021.3% | $5.0M-4.0% | $5.3M |
| Total Equity | $415.4M+17.7% | $352.9M+243.8% | $102.6M |
| Retained Earnings | -$154.5M-1.1% | -$152.9M+18.3% | -$187.1M |
TLX Cash Flow Statement
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A |
TLX Financial Ratios
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|---|---|---|
| Gross Margin | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A |
| Current Ratio | 1.43-1.4 | 2.78+1.4 | 1.42 |
| Debt-to-Equity | 0.14+0.1 | 0.01-0.0 | 0.05 |
| FCF Margin | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Telix Pharmaceuticals Ltd ADR's annual revenue?
Telix Pharmaceuticals Ltd ADR (TLX) reported $803.8M in total revenue for fiscal year 2025. This represents a 55.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Telix Pharmaceuticals Ltd ADR's revenue growing?
Telix Pharmaceuticals Ltd ADR (TLX) revenue grew by 55.6% year-over-year, from $516.6M to $803.8M in fiscal year 2025.
Is Telix Pharmaceuticals Ltd ADR profitable?
No, Telix Pharmaceuticals Ltd ADR (TLX) reported a net income of -$7.1M in fiscal year 2025, with a net profit margin of -0.9%.
How much debt does Telix Pharmaceuticals Ltd ADR have?
As of fiscal year 2025, Telix Pharmaceuticals Ltd ADR (TLX) had $141.9M in cash and equivalents against $56.5M in long-term debt.
What is Telix Pharmaceuticals Ltd ADR's net profit margin?
Telix Pharmaceuticals Ltd ADR (TLX) had a net profit margin of -0.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Telix Pharmaceuticals Ltd ADR's return on equity (ROE)?
Telix Pharmaceuticals Ltd ADR (TLX) has a return on equity of -1.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Telix Pharmaceuticals Ltd ADR's free cash flow?
Telix Pharmaceuticals Ltd ADR (TLX) generated -$43.0M in free cash flow during fiscal year 2025. This represents a -334.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Telix Pharmaceuticals Ltd ADR's operating cash flow?
Telix Pharmaceuticals Ltd ADR (TLX) generated -$17.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Telix Pharmaceuticals Ltd ADR's total assets?
Telix Pharmaceuticals Ltd ADR (TLX) had $1.2B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Telix Pharmaceuticals Ltd ADR's capital expenditures?
Telix Pharmaceuticals Ltd ADR (TLX) invested $25.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Telix Pharmaceuticals Ltd ADR's current ratio?
Telix Pharmaceuticals Ltd ADR (TLX) had a current ratio of 1.43 as of fiscal year 2025, which is considered adequate.
What is Telix Pharmaceuticals Ltd ADR's debt-to-equity ratio?
Telix Pharmaceuticals Ltd ADR (TLX) had a debt-to-equity ratio of 0.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Telix Pharmaceuticals Ltd ADR's return on assets (ROA)?
Telix Pharmaceuticals Ltd ADR (TLX) had a return on assets of -0.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Telix Pharmaceuticals Ltd ADR's cash runway?
Based on fiscal year 2025 data, Telix Pharmaceuticals Ltd ADR (TLX) had $141.9M in cash against an annual operating cash burn of $17.3M. This gives an estimated cash runway of approximately 98 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Telix Pharmaceuticals Ltd ADR's Piotroski F-Score?
Telix Pharmaceuticals Ltd ADR (TLX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Telix Pharmaceuticals Ltd ADR's earnings high quality?
Telix Pharmaceuticals Ltd ADR (TLX) has an earnings quality ratio of 2.43x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Telix Pharmaceuticals Ltd ADR?
Telix Pharmaceuticals Ltd ADR (TLX) scores 44 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.